T1	intervention 14 35	transdermal estradiol
T2	intervention 39 64	oral conjugated oestrogen
T3	intervention 69 80	fenretinide
T4	control 88 95	placebo
T5	condition 99 134	haemostasis and cardiovascular risk
T6	outcome-Measure 560 577	changes in lipids
T7	outcome-Measure 582 598	clotting profile
T8	eligibility 637 658	post-menopausal women
T9	control-participants 724 726	55
T10	intervention-participants 765 767	56
T11	intervention-participants 854 856	56
T12	control-participants 812 814	59
T13	duration 939 948	12 months
T14	outcome 1066 1083	fibrinogen levels
T15	intervention-value 1120 1125	-5.7%
T16	intervention-value 1139 1144	-1.1%
T17	outcome 1166 1183	Total cholesterol
T18	outcome 1220 1225	HDL-C
T19	outcome 1355 1368	Triglycerides
T20	outcome 1519 1535	Antithrombin-III
T21	intervention-value 1545 1547	4%
T22	intervention-value 1427 1432	21.4%
T23	intervention-value 1470 1474	8.6%
